Version July 2025
| Product | Half-life and volume of distribution (VD)* based on patient age | ||
| <6 years | 6 to 12 years | >12 years | |
| Standard half-life products | |||
| AlphaNine SD¶ (plasma-derived, S/D treated) | N/A | N/A | Half-life: 21 hours (≥16 years) VD: 1 |
| BeneFIX (recombinant) | Half-life: 16 hours (<2 years), 17 hours (2 to 6 years) VD: 1.4 | Half-life: 16 hours VD: 1.4 | Half-life: 23 hours VD: 1.3 |
| Ixinity (recombinant) | Half-life: 16 hours VD: 1.27 | Half-life: 17 hours VD: 1.27 | Half-life: 24 hours VD: 1 |
| Rixubis (recombinant) | Half-life: 28 hours VD: 1.4 | Half-life: 23 hours VD: 1.4 | Half-life: 26 hours VD: 1.1 |
| Longer lasting products | |||
| Alprolix (recombinant, Fc fusion) | Half-life: 68 hours VD: 1.7 | Half-life: 72 hours VD: 1.35 | Half-life: 80 to 94 hours (12 to 17 years), 86 to 97 hours (≥18 years) VD: 1 |
| Idelvion (recombinant, albumin fusion) | Half-life: 90 hours VD: 1 | Half-life: 93 hours VD: 1 | Half-life: 87 hours (12 to 17 years), 104 hours (≥18 years) VD: 0.77 |
| Rebinyn (recombinant, glycoPEGylated) | Half-life: 70 hours (<7 years) VD: 0.66 (≤6 years) | Half-life: 76 hours (7 to 12 years) VD: 0.63 (7 to 12 years) | Half-life: 89 hours (≥18 years), 83 hours (13 to 17 years) VD: 0.43 (≥18 years), 0.51 (13 to 17 years) |
This table is intended as a rapid summary of product characteristics. Refer to the product information and UpToDate for details of hemophilia management and clotting factor administration.
Non-factor products are also available for individuals with hemophilia B (fitusiran, marstacimab); refer to UpToDate for details.
Fc: constant regions of immunoglobulin heavy chain (fragment, crystallizable); SD: solvent/detergent treated; VD: volume of distribution.
* These values are approximate. Actual half-life, which determines dosing interval, and actual VD, which determines dose level, should be determined for each individual patient.
¶ Adults only.
